Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention

被引:15
|
作者
Youssef, Ali A.
Wu, Chiung-Jen
Hang, Chi-Ling
Cheng, Cheng-I
Yang, Cheng-Hsu
Chen, Chien-Jen
Chen, Yen-Hsun
Chai, Han-Tan
Chua, Sarah
Yeh, Kuo-Ho
Yip, Hon-Kan
机构
[1] Chang Gung Univ Coll Med, Dept Internal Med, Div Cardiol, Chang Gung Mem Hosp,Kaohsiung Med Ctr, Kaohsiung 83301, Taiwan
[2] Suez Canal Univ Hosp, Dept Cardiol, Ismailia, Egypt
关键词
nitroprusside; no-reflow; PercuSurge device; slow-flow;
D O I
10.1253/circj.70.1538
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The present study tested the hypothesis that when administered in conjunction with a PercuSurge device for treatment of acute myocardial infarction (AMI), intracoronary (IC) administration of nitroprusside (NTP) is safe and superior to IC administration of NTP alone or nitroglycerin (NTG) for reversing slow-flow or no-reflow, both of which occur frequently during primary percutaneous coronary intervention (PCI). Methods and Results Sixty-two patients with ST-segment elevation AMI of < 12h duration undergoing primary PCI were enrolled. When the final Thrombolysis In Myocardial Infarction (TIMI) flow was normal (TIMI-3), NTG 200 mu g was administered first, followed by (5 min later) NTP 100,mu g via an intra-guiding catheter. When final TIMI flow was <= 2, NTG 200 mu g was given, followed by NTP 100 mu g via an export suction catheter advanced into the infract-related artery (IRA). Primary endpoint was epicardial blood flow (TIMI-flow), corrected TIMI frame counts, or microvascular circulation [myocardial blush (MB) grade]. Analytical results indicated that the final TIMI-3 flow was significantly higher in patients receiving NTP than in those receiving NTG therapy (100% vs 88.7%, p=0.023). As compared with NTG, NTP therapy significantly improved final MB grade (p < 0.0001) and corrected TIMI flame count time (p < 0.0001). Subgroup analysis demonstrated that final MB grade (p < 0.001) and corrected TIMI flame count time (p < 0.01) were significantly higher in patients (n=33) with than in patients (n=29) without the PercuSurge. No significant NTP related adverse events occurred, apart from insignificant transient hypotension. Conclusion IC administration of NTP is safe and superior to NTG for improving final epicardial blood flow and microvascular circulation in patients with AMI undergoing primary PCI. Combination therapy of PercuSurge device and NTP provided an additional benefit to NTP alone for improving microvascular circulation.
引用
收藏
页码:1538 / 1542
页数:5
相关论文
共 50 条
  • [21] CHA2DS2-VASc score predict no-reflow phenomenon in primary percutaneous coronary intervention
    Mirbolouk, Fardin
    Gholipour, Mahboobeh
    Salari, Arsalan
    Shakiba, Maryam
    Kheyrkhah, Jalal
    Nikseresht, Vahid
    Sotoudeh, Nozar
    Moghadam, Negar
    Mirbolouk, Mohammad Jaafar
    Far, Mani Moayeri
    JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH, 2018, 10 (01) : 46 - 52
  • [22] Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis
    Niu, Xiaowei
    Zhang, Jingjing
    Bai, Ming
    Peng, Yu
    Sun, Shaobo
    Zhang, Zheng
    BMC CARDIOVASCULAR DISORDERS, 2018, 18
  • [23] The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality
    Choo, Eun Ho
    Kim, Pum Joon
    Chang, Kiyuk
    Ahn, Youngkeun
    Jeon, Doo Soo
    Lee, Jong Min
    Kim, Dong Bin
    Her, Sung-Ho
    Park, Chul Soo
    Kim, Hee Yeol
    Yoo, Ki-Dong
    Jeong, Myung Ho
    Seung, Ki-Bae
    CORONARY ARTERY DISEASE, 2014, 25 (05) : 392 - 398
  • [24] The Systemic Immune Inflammatory Index Predicts No-Reflow Phenomenon after Primary Percutaneous Coronary Intervention in Older Patients with STEMI
    Wang, Jiaqi
    Zhang, Feifei
    Gao, Man
    Wang, Yudan
    Song, Xuelian
    Li, Yingxiao
    Dang, Yi
    Qi, Xiaoyong
    CARDIOVASCULAR INNOVATIONS AND APPLICATIONS, 2022, 7 (01)
  • [25] The Relationship Between Leukocyte Number And No-Reflow Phenomenon Developed After Primary Coronary Intervention
    Erden, Ismail
    Erden, Emine Cakcak
    Yalcin, Subhan
    Basar, Cengiz
    KONURALP TIP DERGISI, 2011, 3 (01): : 18 - 21
  • [26] Intracoronary adenosine compared with adrenaline and verapamil in the treatment of no-reflow phenomenon following primary PCI in STEMI patients
    Arab, Tamer Abu
    Sedhom, Ramy
    Gomaa, Yasser
    El Etriby, Adel
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 410
  • [27] Development of Multi-Vessel Coronary No-Reflow Following Elective Percutaneous Intervention in One Vessel
    Hussain, Syed W.
    Ramsaran, Eddison
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [28] Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction
    Mazhar, Jawad
    Mashicharan, Mary
    Farshid, Ahmad
    IJC HEART & VASCULATURE, 2016, 10 : 8 - 12
  • [29] Verapamil Reverses Myocardial No-Reflow After Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction
    Qiang Fu
    Wen Lu
    Yi-jie Huang
    Qiang Wu
    Lin-guang Wang
    Hai-bo Wang
    Shu-zhong Jiang
    Yan-jiong Wang
    Cell Biochemistry and Biophysics, 2013, 67 : 911 - 914
  • [30] Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction
    Sgueglia, Gregory Angelo
    Niccoli, Giampaolo
    Spaziani, Cristina
    Cosentino, Nicola
    Russo, Eleonora
    Andreotti, Felicita
    Lanza, Gaetano Antonio
    Landolfi, Raffaele
    Crea, Filippo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 145 (02) : 230 - 232